arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Ocugen, Inc.

OCGN
$1.00 ▼ -0.04 (-4.31%) at close
Healthcare ·Biological Products, (No Diagnostic Substances) ·USBiological Products, (No Diagnostic Substances)
51 Visible periods
27 Metrics
Peer-ranked Benchmarks
Price Chart
86
Health
Excellent
Bullish
auto_awesome

Analytical Summary

Ocugen, Inc. shows strong fundamentals with top-quartile Debt to Equity. The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $338.7M
Dividend Yield
Revenue Growth 8.4%
Op. Margin
ROIC 87.6%
FCF / Share $-0.04
Trailing P/E
Price / Book
FCF Yield
Debt / Equity -0.10
info Valuation on last close. End-of-day price, Sep 23, 2026.

51-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$1.49M
↑ +8.4%
Net Income Profit after all expenses
$-19.18M
↓ -24.9%
FCF / Share Free cash flow per share
$-0.04
↑ +2.2%
Long-Term Debt Long-term obligations
$1.73M
↓ -92.9%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Financial Health
100
Cash Quality
57

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 13 years · 51 quarters